Basket | Login | Register


Science watch


Our science watch section reports on the story behind the media-reported “breakthrough” headlines in dementia, by focusing on the original journal study. Reports of other developments in research on care and cure are also included.

12/07/2019 EIP Pharma initiates Phase II study of neflamapimod for dementia with Lewy Bodies
11/07/2019 Novartis and Amgen stop two Phase II/III clinical studies of CNP520 in the Alzheimer's Prevention Initiative Generation programme
07/07/2019 Large retrospective cohort study identifies association between androgen deprivation therapy and Alzheimer’s disease in elderly men with prostate cancer
01/07/2019 SveDem study presented at the 5th European Academy of Neurology congress shows positive association between statin use and survival in people with dementia
27/06/2019 vTv Therapeutics announces Phase II clinical trial evaluating azeliragon in patients with mild AD and type 2 diabetes
26/06/2019 AB Science reports interim analysis for Phase III trial of masitinib for mild to moderate AD
24/06/2019 Clinical study published in JAMA Neurology confirms the accuracy of a new diagnostic blood test for β-amyloid in AD
24/06/2019 A case-control study reports association between anticholinergic drug exposure and dementia risk among people 55 years or older
24/06/2019 Enterin announces Phase I study evaluating ENT-01 for Parkinson's disease dementia
20/06/2019 Large-scale MindCrowd study shows early cognitive deficits in participants with a family history of AD
14/06/2019 French scientists publish an investigation into a new tool to help differentiate between frontotemporal dementia and AD
05/06/2019 Researchers identify brain alterations that may occur during the preclinical phase of AD
03/06/2019 Researchers develop vaccine that could reduce accumulation of Tau in mouse models
01/06/2019 Study investigates the influence of sex, genes and age on the duration of AD stages and reports on individual stage duration
01/06/2019 The Alzheimer's Clinical Trials Consortium selects Elenbecestat and BAN2401 for upcoming clinical trials on AD prevention